|
“12-Year Outcomes Following Permanent Prostate Brachytherapy in Patients with Clinically Localized Prostate Cancer”
Louis Potters, Carol Morgenstern, Emil Calugaru, Paul Fearn, Anup Jassal, Joseph Presser and Edward Mullen The Journal of Urology 173 (2005) 1562-1566
Physicians reviewed the postoperative
outcomes of 1,449 consecutive prostate cancer patients
treated with permanent brachytherapy
between 1992 and 2000. These patients were generally
around 68 years old with a prostate
specific antigen level of 10.1, 55 percent had a
Gleason
score of 6 and 28 percent had a Gleason score of
7. For many, brachytherapy was not their initial or
only treatment. There were 400 patients (27%) who received
neoadjuvant
hormone therapy and 301 (20%) received a combination
of external radiation and brachytherapy. After 82 months,
39 patients were at risk for 144 months. The overall
survival rate 12 years following was 81 percent and
the disease specific survival rate was 93 percent. After
12 years the American Society for Therapeutic Radiology
and Oncology (ASTRO) defined the biochemical-free
recurrence at 81 percent, ASTRO-Kattan at 78 percent,
ASTRO-Last Call at 74 percent, and Houston at 77 percent.
Using the ASTRO-Kattan definition, patients at low risk
could achieve 89 percent biochemical-free recurrence,
those at intermediate risk 78 percent, and those at
high risk 63 percent.
“European Collaborative Group on Prostate Brachytherapy: Preliminary Report in 1175 Patients.”
S. Langleya, R. Laingb, A. Hendersona, S. Aaltomaac, V. Katajad, J.-E. Palmgrend, F. Bladoue, N. Salemf, G. Sermente, L. Navag, A. Losah, G. Guazzonih, F. Guedeai, F. Aguiloj, J.F. Suarezj
European Urology 46 (2004) 565570
The goal of this study was to create
a multi-center database of a large span of prostate
cancer patients treated with brachytherapy across Europe.
To reach this goal 1,175 patients files were included,
all of which were registered due to the comprehensive
data presented. A patient follow-up was given at five
years. Prior hormone therapy treatments were reported
in 492 of 1,175 patients (41.9%). France, UK, and Finland
reported administering 270 of 860 (31.4%) patients with
an antiandrogen and 206 of 860 (24.0%) with a luteinising
hormone-releasing hormone (LHRH). Also, 118 patients
from France and Italy received electron beam radiation
therapy. After a thorough analysis of the database,
the study revealed that patient selection has been made
optimal both in terms of brachytherapy outcomes and
side effects. These results prove that physicians are
able to refine treatment choice and administration for
their patients. Furthermore, the database indicates
that brachytherapy is a well-established treatment option
for prostate cancer.
|
|
|
